Digest Network Come funziona
Network
/
Società
Sy
Non verificato

Sydnexis, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOtticaSalute

10 comunicati stampa

Guarda tutti i comunicati
01/05/2026
Industria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Ottica
Sydnexis to Present New Data from Phase 3 STAR Trial of SYD-101 at ARVO 2026 Annual Meeting
Fonte
Sydnexis, Inc.
Emittente
Business Wire
1.00
0
23/03/2026
Salute
Vetrine/Shopping
Infanzia
Medicina - Varie
Farmaceutica
Ottica
Biotecnologia
Sydnexis Announces New Data from Phase 3 STAR Trial of SYD-101 Presented at 2026 AAPOS Annual Meeting
Fonte
Sydnexis, Inc.
Emittente
Business Wire
1.00
0
06/11/2025
Biotecnologia
Salute
Farmaceutica
Ottica
Medicina - Varie
Industria
Sydnexis Announces UK Approval of Ryjunea® by Partner Santen to Slow Progression of Childhood Myopia
Fonte
Sydnexis, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Industria
Scienza
Sanità
Farmaceutica
Ottica
Vetrine/Shopping
Medicina - Varie
Infanzia
Pubblico Esercizio/Vendita al dettaglio
Biotecnologia
Salute
Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025
Fonte
Sydnexis, Inc.
Emittente
Business Wire
1.00
0
23/10/2025
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Ottica
Biotecnologia
Sydnexis Receives Complete Response Letter from FDA for SYD-101 to Slow Pediatric Myopia Progression
Fonte
Sydnexis, Inc.
Emittente
Business Wire
1.00
0
05/06/2025
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Fonte
Sydnexis, Inc.
Emittente
Business Wire
1.00
0
01/05/2025
Fiere
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Ottica
Medicina - Varie
Sydnexis Announces Three Abstracts Accepted for Poster Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Fonte
Sydnexis, Inc.
Emittente
Business Wire
1.00
0
01/04/2025
Mercato del lavoro
Industria
Biotecnologia
Salute
Farmaceutica
Ottica
Medicina - Varie
Sydnexis Announces Positive CHMP Opinion in Europe for SYD-101 for Slowing the Progression of Pediatric Myopia
Fonte
Sydnexis, Inc.
Emittente
Business Wire
1.00
0
11/03/2025
Industria
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Ottica
Biotecnologia
Sydnexis Announces FDA Acceptance of New Drug Application for SYD-101 for the Treatment of Progression of Pediatric Myopia
Fonte
Sydnexis, Inc.
Emittente
Business Wire
1.00
0
16/07/2024
Biotecnologia
Salute
Farmaceutica
Ottica
Medicina - Varie
Mercato del lavoro
Industria
Perry J. Sternberg Joins Sydnexis as Chief Executive Officer
Fonte
Sydnexis, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0